Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products.
Rosen said it makes a big difference how a product is classified and which FDA office reviews it. “People would love products, for example, to be medical devices when they possibly can because it’s a lot less expensive and the time frame is generally a lot shorter,” he said.
He also said one proposed change – which would clarify that only product sponsors (such as drug companies or device makers) can submit a request for designation to suggest how a product should be classified and which office should be assigned to review it – is likely to be challenged because sponsors don’t always want to be identified early in the development process. “They want to keep things confidential so they engage us lawyers to write these requests without definitely identifying who they are,” he said.
Subscription required.
Rosen said it makes a big difference how a product is classified and which FDA office reviews it. “People would love products, for example, to be medical devices when they possibly can because it’s a lot less expensive and the time frame is generally a lot shorter,” he said.
He also said one proposed change – which would clarify that only product sponsors (such as drug companies or device makers) can submit a request for designation to suggest how a product should be classified and which office should be assigned to review it – is likely to be challenged because sponsors don’t always want to be identified early in the development process. “They want to keep things confidential so they engage us lawyers to write these requests without definitely identifying who they are,” he said.
Subscription required.
People
Related News
April 13, 2026
In the News
Increase in Demand and Firm Growth Led Foley to Large Leaps in Revenue and PEP in a 'Year When It All Came Together'
Foley & Lardner LLP saw double-digit increases and all-time highs across all financial metrics in 2025 as noted in The American Lawyer article, “Foley Grows Revenue by Nearly 14%, PEP by 27%, in a 'Year When It All Came Together'.”
April 10, 2026
In the News
Foley's Texas Media Roundtable Highlighted for Insights on Today's Energy Transformations
Foley & Lardner LLP is featured across media for the firm’s recent roundtable discussion on energy trends related to grid reliability, data centers, and capital investments.
April 10, 2026
In the News
Deanna Reitman and Glenn Reitman Highlighted Across Media for Foley Arrival
Foley & Lardner LLP partners Deanna Reitman and Glenn Reitman attracted widespread media coverage for their recent arrival to the firm’s Houston office.